Advert - Daiichi Sankyo – Case AUTH/3649/5/22

For failing to make immediately apparent to health professionals in the body of promotional material which referred to the therapeutic use of Nilemdo (bempedoic acid) or Nustendi (bempedoic acid and ezetimibe) in combination with a statin that there was a contraindication regarding concomitant use with simvastatin >40mg daily, and for failing to comply with its undertaking provided in Case AUTH/3504/2/21, Daiichi Sankyo was ruled in breach of the following Clauses of the 2021 Code:

Clause 2           - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 3.3        - Failing to comply with an undertaking

Clause 5.1        - Failing to maintain high standards

Clause 6.1        - Misleading impression provided